Latest Strategy Changes News

Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.

Larvotto Resources is progressing the Hillgrove Antimony-Gold Project on time and budget, aiming for mid-2026 production amid rising strategic demand for antimony. The project benefits from grid power, ongoing drilling success, and government support for critical minerals.

Riversgold Limited has reported standout assay results from 31 drill holes at its Northern Zone Gold Project, including a spectacular 71 g/t gold intercept. The campaign expands the shallow gold mineralisation footprint, supporting imminent mining lease conversion and a funding agreement with MEGA Resources.

WhiteHawk Limited has raised A$1.5 million through a share placement to fund integration and growth of its newly acquired Quixxi Clarity AI platform, marking a strategic push into the AI governance market.

Xenitra Limited has acquired Hong Kong Fukang Trading Co., including key pharmaceutical licenses and ecommerce assets, to fully operationalise its OTC medicine business in Hong Kong and China.

Strategic Energy Resources has locked in a binding joint venture with Sumitomo Metal Mining Oceania to explore its Bulimba Gold Project in northeast Queensland, with Sumitomo able to earn up to 90% through staged commitments over five years.

Qoria Limited and Aura have pushed back their merger timeline to July 2026 amid transaction complexities, with Aura providing a A$10 million unsecured working capital facility to support Qoria through the interim period.

Shine Justice reshuffles its top management as Simon Morrison steps down from Managing Director to Executive Director to spearhead international growth, particularly in its burgeoning mass torts program, while Carolyn Barker AM maintains overall CEO leadership.

Duratec's joint venture with Ertech has clinched a $281 million contract to upgrade submarine infrastructure at HMAS Stirling, marking a major step in Australia's AUKUS defence preparations.

Cuscal Limited has successfully raised A$30 million through a fully underwritten institutional placement to fund its acquisition of Paymark. The company also launched a Share Purchase Plan targeting an additional A$3 million from eligible shareholders.

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.

Southern Palladium's latest metallurgical test work from its Bengwenyama PGM Project reveals a doubling in chromite concentrate recoveries and confirms the high-grade nature of its UG2 mineral resource, reshaping project economics and processing design.